Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) Director Anthony G. Quinn bought 4,100 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were purchased at an average cost of $4.53 per share, for a total transaction of $18,573.00. Following the completion of the transaction, the director now owns 14,100 shares of the company’s stock, valued at $63,873. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) traded down $0.34 during midday trading on Tuesday, reaching $4.74. The company’s stock had a trading volume of 76,239 shares, compared to its average volume of 65,901. Aeglea Bio Therapeutics Inc has a 12 month low of $2.81 and a 12 month high of $8.14.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.07. The company had revenue of $1.26 million for the quarter. Aeglea Bio Therapeutics had a negative return on equity of 44.05% and a negative net margin of 527.99%. equities research analysts predict that Aeglea Bio Therapeutics Inc will post -1.97 EPS for the current fiscal year.

Separately, Zacks Investment Research downgraded Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 19th.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGLE. Susquehanna International Group LLP acquired a new stake in Aeglea Bio Therapeutics during the second quarter valued at approximately $653,000. Renaissance Technologies LLC acquired a new stake in Aeglea Bio Therapeutics during the first quarter valued at approximately $270,000. Bank of New York Mellon Corp acquired a new stake in Aeglea Bio Therapeutics during the first quarter valued at approximately $157,000. Finally, Vanguard Group Inc. boosted its holdings in Aeglea Bio Therapeutics by 9.4% during the second quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock valued at $579,000 after purchasing an additional 12,966 shares in the last quarter. 46.89% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Receive News & Ratings for Aeglea Bio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics Inc and related companies with's FREE daily email newsletter.